# US 2026/0076952 A1 · Agent for Treatment of Neutropenia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076952 A1
- Document ID: US20260076952A1
- Status: Published application
- Kind: A1
- Application number: 19/334,162
- Filed: 2025-09-19
- Published: 2026-03-19
- Earliest claimed: 2023-03-22
- Assignees: Eberhard Karls Universität Tübingen Medizinische Fakultät
- Applicants: Eberhard Karls Universität Tübingen Medizinische Fakultät
- Inventors: Julia Skokowa; Masoud Nasri; Benjamin Dannenmann; Larissa Doll
- Web page: https://patentgrep.com/patent/US20260076952A1

## CPC

- A61K 31/453: containing a six-membered ring with oxygen as a ring hetero atom
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 37/00: Drugs for immunological or allergic disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a new agent for the prophylaxis and/or treatment of neutropenia, a pharmaceutical composition comprising said agent, and to a method for the prophylactic and/or therapeutic treatment of neutropenia.

## Claims

### Claim 1

A method for the prophylactic or therapeutic treatment of neutropenia in a living being, comprising the administration of an effective amount of a cyclin-dependent kinase 2/4/9 (CDK2/4/9) inhibitor or salts thereof, solvates thereof and solvates of the salts thereof, to said living being.

### Claim 2 (depends on 1)

The method of claim 1, wherein the CDK2/4/9 inhibitor is selected from the group consisting of: flavopiridol (alvocidib), rohitukine, TP-1287, seliciclib (roscovitine/CYC202), dinaciclib (SCH 727965), SNS 032, P276-00, AT7519, voruciclib, CDKI-73, TG02, BAY1143572 (atuveciclib), BAY1251152, AZD4573, i-CDK9, and NVP-2.

### Claim 3 (depends on 1)

The method of claim 1, wherein said neutropenia is any selected from the group consisting of: congenital neutropenia, acquired neutropenia, severe congenital neutropenia (CN/SCN), cyclic neutropenia (CyN), chronic neutropenia, idiopathic neutropenia, drug-induced neutropenia, immune neutropenia, acute neutropenia caused by chemotherapy or radiation.

### Claim 4 (depends on 1)

The method of claim 1, wherein said CDK2/4/6 inhibitor is flavopiridol (alvocidib).

### Claim 5 (depends on 1)

The method of claim 1, wherein the inhibitor is used at a dosage which, after administration into the living being, results in blood plasma concentrations which are in an area selected from the group consisting of: approx. 10-approx. 300, approx. 20-approx. 200, approx. 30-approx. 100, and approx. 40 nM.

### Claim 6 (depends on 1)

The method of claim 1, wherein the neutropenia is severe congenital neutropenia (CN/SCN) or cyclic neutropenia (CyN).

### Claim 7 (depends on 1)

The method of claim 1, wherein the CDK2/4/6 inhibitor is administered to a living being who does not respond or does not respond satisfactorily to treatment with granulocyte colony-stimulating factor (G-CSF).

### Claim 8 (depends on 7)

The method of claim 7, wherein the G-CSF is recombinant human G-CSF (rhG-CSF).

### Claim 9 (depends on 1)

The method of claim 1, wherein said CDK2/4/6 inhibitor is administered to said living being in combination with G-CSF.

### Claim 10 (depends on 9)

The method of claim 9, wherein the G-CSF is rhG-CSF.

### Claim 11

A pharmaceutical composition for the prophylaxis or treatment of neutropenia comprising an CDK2/4/9 inhibitor or salts thereof, solvates thereof or solvates of the salts thereof and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, further comprising G-CSF.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the G-CSF is rhG-CSF.